Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;33(5):e13475.
doi: 10.1111/dth.13475. Epub 2020 May 19.

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

Giovanni Damiani  1   2 , Alessia Pacifico  3 , Nicola L Bragazzi  4 , Piergiorgio Malagoli  5
Affiliations

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

Giovanni Damiani et al. Dermatol Ther. 2020 Sep.

Abstract

During COVID-19 outbreak there are discordant opinions toward the impact of biologics in psoriatic (PsO) patients. Thus we performed a single-center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and five hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to test positive for COVID-19 (odds ratio [OR] 3.43 [95% confidence interval (CI) 2.25-5.73], P < .0001), to be self-quarantined at home (OR 9.05 [95% CI 5.61-14.61], P < .0001) and hospitalized (OR 3.59 [95% CI 1.49-8.63], P = .0044), however, not increased risk of ICU admission or death were found. PsO patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm.

Keywords: COVID-19; SARS-CoV-2; bilateral interstitial pneumonia; biologics; pandemic; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
COVID‐19 disease states and biologics impact
See this image and copyright information in PMC

References

    1. Zhang G, Hu C, Luo L, et al. Clinical features and short‐term outcomes of 221 patients with COVID‐19 in Wuhan, China. J Clin Virol. 2020;127:104364. - PMC - PubMed
    1. Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147‐1157. - PMC - PubMed
    1. Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int. 2018;2018:3140682. - PMC - PubMed
    1. Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7(7):CD011972. - PMC - PubMed
    1. Siddiqi HK, Mehra MR. COVID‐19 illness in native and immunosuppressed states: a clinical‐therapeutic staging proposal. J Heart Lung Transpl. 2020.39(5):405‐407. - PMC - PubMed

Substances